CL2020003324A1 - Composiciones y métodos para inhibir masp-2 para el tratamiento de diversas enfermedades y trastornos trombóticos. - Google Patents

Composiciones y métodos para inhibir masp-2 para el tratamiento de diversas enfermedades y trastornos trombóticos.

Info

Publication number
CL2020003324A1
CL2020003324A1 CL2020003324A CL2020003324A CL2020003324A1 CL 2020003324 A1 CL2020003324 A1 CL 2020003324A1 CL 2020003324 A CL2020003324 A CL 2020003324A CL 2020003324 A CL2020003324 A CL 2020003324A CL 2020003324 A1 CL2020003324 A1 CL 2020003324A1
Authority
CL
Chile
Prior art keywords
methods
compositions
disorders
treatment
activation
Prior art date
Application number
CL2020003324A
Other languages
English (en)
Inventor
Gregory A Demopulos
Thomas Dudler
Bo Nilsson
Original Assignee
Omeros Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corp filed Critical Omeros Corp
Publication of CL2020003324A1 publication Critical patent/CL2020003324A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En un aspecto, la invención proporciona composiciones y métodos para prevenir, reducir, y/o tratar una enfermedad, trastorno o afección asociado con activación inducida por fibrina del sistema del complemento y la activación asociada de los sistemas de coagulación y/o contacto que comprenden administrar una cantidad terapéutica de un anticuerpo inhibidor de MASP-2 a un sujeto que necesita del mismo. En algunas modalidades, los métodos de la invención proporcionan anticoagulación y/o antitrombosis y/o antitrombogénesis sin afectar la hemostasia. En una modalidad de este aspecto de la invención, las composiciones y métodos son útiles para tratar a un sujeto que padece de, o está en riesgo de desarrollar, una enfermedad, trastorno o afección asociada con inflamación relacionada con el complemento, coagulación excesiva o activación del sistema de contacto iniciada por fibrina o plaquetas activadas.
CL2020003324A 2018-06-22 2020-12-21 Composiciones y métodos para inhibir masp-2 para el tratamiento de diversas enfermedades y trastornos trombóticos. CL2020003324A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862688611P 2018-06-22 2018-06-22

Publications (1)

Publication Number Publication Date
CL2020003324A1 true CL2020003324A1 (es) 2021-04-23

Family

ID=68984236

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020003324A CL2020003324A1 (es) 2018-06-22 2020-12-21 Composiciones y métodos para inhibir masp-2 para el tratamiento de diversas enfermedades y trastornos trombóticos.

Country Status (18)

Country Link
US (3) US20200140570A1 (es)
EP (1) EP3836965A4 (es)
JP (1) JP2021527698A (es)
KR (1) KR20210024003A (es)
CN (1) CN112638417A (es)
AU (2) AU2019288459B2 (es)
BR (1) BR112020025841A2 (es)
CA (1) CA3104083A1 (es)
CL (1) CL2020003324A1 (es)
EA (1) EA202190106A1 (es)
GE (3) GEAP202515541A (es)
IL (1) IL279588A (es)
JO (1) JOP20200328A1 (es)
MA (1) MA53234A (es)
MX (1) MX2020013755A (es)
PH (1) PH12020552188A1 (es)
SG (1) SG11202012627UA (es)
WO (1) WO2019246367A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI867422B (zh) * 2020-03-06 2024-12-21 美商奥默羅斯公司 用於治療和/或預防流感病毒誘導的急性呼吸窘迫症候群、肺炎或者流感病毒感染的一些其它肺部表現的抑制masp-2的方法
CN120173118B (zh) * 2020-12-16 2025-09-16 康诺亚生物医药科技（成都）有限公司 一种补体抑制剂的开发和应用
AU2022216290A1 (en) * 2021-02-05 2023-09-14 Omeros Corporation Biomarker for assessing the risk of developing acute covid-19 and post-acute covid-19
JP2024518724A (ja) * 2021-04-25 2024-05-02 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 抗ｍａｓｐ２抗体、その抗原結合断片および医薬用途
AU2022288660A1 (en) * 2021-06-08 2024-01-18 Jiangxi Jemincare Group Co., Ltd. Anti-masp-2 antibody and use thereof
CN116615544A (zh) * 2021-12-10 2023-08-18 舒泰神（北京）生物制药股份有限公司 特异性识别masp2的抗体及其应用
EP4489782A4 (en) * 2022-03-10 2026-03-25 Omeros Corp MASP-2 and MASP-3 inhibitors, and associated compositions and methods for the treatment of sickle cell disease
CN115125299A (zh) * 2022-08-09 2022-09-30 大连珍奥药业股份有限公司 Masp1在筛选预防和/或治疗心血管疾病的药物中的应用
JP2025541737A (ja) 2022-11-30 2025-12-23 オメロス コーポレーション Ｍａｓｐ－２阻害物質としての縮合ピリミジン
WO2025076476A2 (en) 2023-10-06 2025-04-10 Omeros Corporation Masp-2 inhibitors and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004216176B2 (en) * 2003-02-21 2008-04-03 Genentech, Inc. Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
ES2541134T3 (es) * 2003-05-12 2015-07-16 Helion Biotech Aps Anticuerpos de MASP-2
PL2465534T3 (pl) * 2004-06-10 2017-08-31 Omeros Corporation Sposoby leczenia stanów związanych z aktywacją dopełniacza zależną od masp-2
US8840893B2 (en) * 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20140056873A1 (en) * 2004-06-10 2014-02-27 University Of Leicester Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
WO2006033386A1 (ja) * 2004-09-22 2006-03-30 Kirin Beer Kabushiki Kaisha 安定化されたヒトIgG4抗体
US20150166676A1 (en) * 2011-04-08 2015-06-18 Omeros Corporation Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
KR20200015952A (ko) * 2012-06-18 2020-02-13 오메로스 코포레이션 다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법
LT3057993T (lt) * 2013-10-17 2020-11-25 Omeros Corporation Gydymo būdai būklių, susijusių su nuo masp-2 priklausomu komplemento aktyvinimu
US20150353623A1 (en) * 2014-04-03 2015-12-10 Loma Linda University Substances and methods for the treatment of cerebral amyloid angiopathy related conditions or diseases
US20170137537A1 (en) * 2015-11-09 2017-05-18 Omeros Corporation Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation

Also Published As

Publication number Publication date
AU2019288459B2 (en) 2025-11-13
GEP20257785B (en) 2025-08-11
MA53234A (fr) 2022-04-20
AU2026200868A1 (en) 2026-02-26
GEP20267851B (en) 2026-01-26
JOP20200328A1 (ar) 2020-12-15
CN112638417A (zh) 2021-04-09
CA3104083A1 (en) 2019-12-26
GEAP202515541A (en) 2025-03-10
US20230212314A1 (en) 2023-07-06
WO2019246367A1 (en) 2019-12-26
AU2019288459A1 (en) 2021-02-04
MX2020013755A (es) 2021-05-12
US20200140570A1 (en) 2020-05-07
US20260062499A1 (en) 2026-03-05
IL279588A (en) 2021-03-01
EP3836965A4 (en) 2022-04-20
JP2021527698A (ja) 2021-10-14
BR112020025841A2 (pt) 2021-03-23
KR20210024003A (ko) 2021-03-04
SG11202012627UA (en) 2021-01-28
EA202190106A1 (ru) 2021-04-13
PH12020552188A1 (en) 2021-06-28
AU2019288459A2 (en) 2021-03-18
EP3836965A1 (en) 2021-06-23

Similar Documents

Publication Publication Date Title
CL2020003324A1 (es) Composiciones y métodos para inhibir masp-2 para el tratamiento de diversas enfermedades y trastornos trombóticos.
ECSP19044183A (es) (aza)indol-, benzotiofen, y benzofuran-3-sulfonamidas
EA202191185A1 (ru) Способы ингибирования ангиогенеза у пациента
EP3955839A4 (en) DEVICES, SYSTEMS AND METHODS FOR TREATMENT OF ABNORMAL TISSUE
MX2023008368A (es) Uso de antagonista de il-33 o un antagonista de il-4r en la fabricacion de un medicamento para tratar enfermedades o trastornos inflamatorios.
MX2020010469A (es) Inhibidores del atf6 y sus usos.
MX2016005017A (es) Metodos para el tratamiento de condiciones asociadas con la activacion del complemento dependiente de masp-2.
MX2018008331A (es) Metodos para la inhibicion de fibrosis en un sujeto en necesidad del mismo.
SA520411703B1 (ar) أجسام مضادة لترانس ثيرتين
EP3368560A4 (en) CPG REDUCED FACTOR VIII VARIATIONS, COMPOSITIONS AND METHODS AND USES FOR THE TREATMENT OF HEMOSTASIS
EA201890394A1 (ru) КОМПОЗИЦИИ НА ОСНОВЕ iRNA ДЛЯ ТРАНСТИРЕТИНА (TTR) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДУПРЕЖДЕНИЯ АССОЦИИРОВАННЫХ С TTR ЗАБОЛЕВАНИЙ
CL2019003789A1 (es) Tratamiento con plasminógeno de afecciones asociadas a la sobreexpresión de pai-1.
CR20190468A (es) Métodos para tratar enfermedades y trastornos mediados por completo
PE20180556A1 (es) Anticuerpos inhibidores via del factor tisular y usos de los mismos
AR115583A1 (es) Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado
CL2022001708A1 (es) Decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis
MX2019001633A (es) Proteina derivada de la seda para el tratamiento de la inflamacion.
MX2021011507A (es) Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento.
WO2019165158A8 (en) Il-6 inhibitors and methods of treatment
CL2019003485A1 (es) Métodos para redicur la proteinuria en un sujeto humano que padece de nefropatía por inmunoglobulina a. (divisional solicitud 201900909)
EP3755278A4 (en) RESORBABLE INTRAVASCULAR DEVICES FOR TREATMENT OF VEIN OCCLUSION
MX2020008146A (es) Proteinas anticoagulantes y su uso para tratar enfermedades asociadas a la activacion de neutrofilos.
MX2021000601A (es) Metodos de tratamiento de hfpef empleando dapagliflozina y composiciones que comprenden la misma.
CL2024001421A1 (es) Uso de composición que comprende un anticuerpo anti masp-2 para tratar síndrome de neumonìa idiopàtica.
MX375272B (es) Ciclodextrinas como procoagulantes